Aclin (Sulindac) is indicated for the management of symptoms related to physical discomfort, such as pain, tenderness, swelling, and stiffness. The medication may be part of symptomatic management in situations where patients experience inflammatory or irritative states.

Supportive Management of Chronic Arthritis

Aclin is commonly used across conditions involving episodic or fluctuating manifestations, such as Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis. It is applied across therapeutic domains where additional symptomatic support is needed, helping to address symptom clusters that include chronic joint pain, tenderness, and morning stiffness. This assists with maintaining functional stability and helps improve day-to-day comfort during symptomatic periods.

Relief for Acute Inflammatory Episodes

The medication may be used when short-term symptomatic assistance is appropriate, often applied during phases when symptoms become more noticeable, such as an acute Gouty Arthritis flare-up or inflammatory syndromes like Bursitis and Tendinitis of the shoulder. It is used for managing symptoms that interfere with daily comfort, such as localized swelling and pain.

Quick Fact: Relevant for Easing Symptoms Related to Inflammation and Pain

Systemic Control of Pain, Swelling, and Fever

Aclin is used to support the management of symptoms during episodes of heightened discomfort from symptom clusters that may become temporarily overwhelming. It plays a role in managing the core physical symptoms associated with the inflammatory response, contributing to improved comfort during periods of heightened symptoms, which may assist with managing physical discomfort and systemic imbalance.

Regulatory References

1. NIH MedlinePlus Drug Information overview

Who Can and Cannot Use Aclin?

Aclin (Sulindac) eligibility is strictly defined by regulatory documents, primarily restricting use based on age, physiological state, and co-existing conditions.

Contraindications and Absolute Exclusions

Use is absolutely contraindicated for patients with a known hypersensitivity or allergic-type reactions to sulindac, aspirin, or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs). The medicine must not be used for pain in the setting of Coronary Artery Bypass Graft (CABG) surgery. Late-term pregnancy (at 30 weeks gestation and later) is also an absolute exclusion.

Restricted and Conditional Use

Use is not recommended for the pediatric population as safety and efficacy have not been established. Older adults are subject to increased risk for serious gastrointestinal events. Patients with severe renal impairment must avoid use. Those with hepatic impairment (liver dysfunction) or a history of stomach ulcers/bleeding must use the medicine only under close monitoring and specialized assessment. During mid-term pregnancy (20 to 30 weeks gestation), use should be limited in dose and duration, and generally avoided. Safety for nursing mothers has not been established.

Interactions with other medicines and products

Official regulatory documents classify interaction patterns for Aclin (Sulindac) based on effects related to pharmacodynamics, drug exposure, and procedural restrictions. The medication is formally contraindicated for the treatment of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Documented Pharmacodynamic Interactions

Co-administration with several medicinal product classes is documented to create additive or diminished effects:

• Oral Anticoagulants (e.g., Warfarin) and Oral Corticosteroids are noted to increase the risk of serious gastrointestinal adverse events, including bleeding, due to additive effects.
• Diuretics (e.g., Thiazides) and ACE-Inhibitors may experience a diminished therapeutic effect when co-administered with Aclin.
• Regular consumption of alcohol is also documented to increase the risk of serious gastrointestinal events.

Exposure-Modifying Interactions

• Aclin may elevate plasma lithium levels by reducing its renal clearance, potentially leading to toxicity.
• Concomitant use of Aspirin is documented to significantly decrease plasma levels of the active sulfide metabolite of Sulindac.
• Co-administration with Methotrexate has been reported to enhance toxicity due to inhibition of accumulation.

Population-Specific Cautions

Regulatory information notes that elderly patients face a greater risk for serious gastrointestinal adverse events during co-administration with other interacting substances.

Aclin's mechanism of action is dependent on a required metabolic conversion (pro-drug activation) in the liver, which reduces the administered Sulindac into the active compound, Sulindac Sulfide (SSi).

This active metabolite functions as a reversible, non-selective inhibitor of the Cyclooxygenase (COX-1 and COX-2) enzymes. By blocking the COX enzymes, the mechanism leads to a reduction in the synthesis of prostaglandins, specifically Prostaglandin E2 ( PGE2), which are key physiological mediators.

This modulation occurs both peripherally, attenuating the sensitization of peripheral nociceptors, and centrally, modulating the hypothalamic temperature set point. Furthermore, the active agent is subject to reversible deactivation (redox cycling) back into inactive forms, a process that influences the local concentration and properties of the agent's metabolic cycling.

How to Use Aclin

This section describes the general principles of Aclin (Sulindac) use, outlining administration routes, standard dosing ranges, frequency, and specific intake conditions.

---

Administration Route and Frequency

The medicine is supplied as an oral tablet and must be administered by mouth. The standard schedule for all approved uses is a fixed frequency of twice daily (b.i.d.). Taking the tablets with a full glass of water is generally recommended. The tablet is generally taken with food or milk.

---

Dosing Regimens and Maximum Limits

Administration typically follows a pattern of 150 mg to 200 mg taken twice daily, although the exact dose may be adjusted based on the specific condition being managed. Regardless of the regimen, the total administration of Aclin must not exceed the maximum dosage of 400 mg per day. The dose should be administered at approximately 12-hour intervals to maintain a consistent therapeutic pattern.

---

Duration and Special Use Contexts

Use patterns vary with the duration of management required. For acute inflammatory episodes, such as acute gouty arthritis or painful shoulder (bursitis/tendinitis), use is generally limited to a short course, often between 7 and 14 days. For chronic conditions like rheumatoid arthritis, use is typically ongoing as part of a long-term plan. If a dose is missed, it should be skipped if it is almost time for the next scheduled dose, and the standard approach is not to take two doses to compensate.

Research evidence / Overview of studies for Aclin (Sulindac)

This overview describes the types of research and clinical trials that have been conducted to evaluate the use of Aclin (Sulindac), focusing on what was studied and what aspects of the evidence are still being explored, as documented by official sources.

---

Evidence for Use in Chronic Arthritis Conditions

Aclin was studied for use in conditions such as Osteoarthritis (OA) and Rheumatoid Arthritis (RA), which are characterized by fluctuating or episodic manifestations of pain and stiffness. The evidence base includes many Randomized Controlled Trials (RCTs) and subsequent reviews. These studies typically enrolled adult patients with confirmed conditions and focused on outcomes related to physical discomfort.

In these trials, researchers examined patient-reported outcomes describing perceived discomfort, such as changes in joint pain scores and measurements of morning stiffness. Research also evaluated how symptom variability evolved in the observed populations by using standardized indices to assess functional stability and activity level over short periods.

However, the existing studies provide limited insight into the drug’s role in long-term structural or disease progression changes. Follow-up durations were often limited, focusing heavily on immediate symptom variability. Comparative evidence against certain other prescription NSAIDs is also less common in the primary literature. Long-term outcomes are not well characterized.

---

Evidence for Use in Acute Inflammatory Episodes

Research has examined the use of Aclin for acute conditions such as disruptive episodes, like an acute Gouty Arthritis flare or acute soft tissue inflammation. These studies were typically short-term RCTs, conducted during periods of increased symptom activity, and focused on outcomes describing episodic or acute changes.

In these trials, the primary outcomes related to inflammatory or irritative states that were examined included measures of localized pain and swelling in the affected area. Studies report how symptoms evolved in observed populations over a very short duration, often lasting only a few days.

Research provides limited insight into long-term disease management, such as tracking chronic biomarkers, and data for long-term functional stability after the acute phase are limited. The overall evidence base for acute inflammation is more limited and is derived from a smaller body of dedicated research compared to that for chronic arthritis.

Key Studies & References

1. Sulindac - StatPearls: Review of Indications, Mechanism, and Clinical Use (for all approved indications)

Common questions about Aclin (FAQ)

Q: What is Aclin used for?

A: Aclin is primarily used to treat infections caused by bacteria, such as certain respiratory tract infections (like pneumonia and bronchitis), skin and soft tissue infections, and ear infections.

Q: How does Aclin work?

A: Aclin is an antibiotic that belongs to a class of drugs called macrolides. It works by stopping the growth of bacteria. Specifically, Aclin interferes with the bacteria's ability to produce essential proteins that they need to survive and multiply. By preventing this protein synthesis, Aclin effectively kills the bacteria or prevents their spread.

Q: Who should not take Aclin?

A: You should not take Aclin if you have a known history of allergic reaction or hypersensitivity to Aclin, any other macrolide antibiotic (like erythromycin or clarithromycin), or any of the inactive ingredients in the medication. It is also not recommended for patients with a history of cholestatic jaundice or hepatic dysfunction associated with prior use of Aclin. Always discuss your full medical history with your healthcare provider before starting Aclin.

Q: What are the common side effects of Aclin?

A: The most common side effects of Aclin generally involve the gastrointestinal system and may include:

• Nausea
• Vomiting
• Diarrhea
• Abdominal pain or discomfort

Other common side effects can include headache and dizziness. These effects are usually mild and temporary. If any side effects persist or worsen, contact your healthcare provider.

Q: Can Aclin interact with other medications?

A: Yes, Aclin can interact with several other medications, which may affect how Aclin or the other medicine works. It is critical to inform your healthcare provider about all prescription, non-prescription, and herbal products you are currently taking, especially:

• Anticoagulants (blood thinners)
• Digoxin (for heart failure)
• Ergotamine and dihydroergotamine (for migraines)
• Antacids containing aluminum or magnesium
• Statins (for high cholesterol)

These are not complete lists, and a pharmacist or doctor can review your specific medications for potential interactions.

Q: Is Aclin safe to take during pregnancy or while breastfeeding?

A: The use of Aclin during pregnancy should only occur if clearly needed, and the potential benefits outweigh the potential risks to the fetus. It is known that Aclin passes into breast milk in small amounts. Therefore, a healthcare provider should assess the benefits of treatment for the mother against the potential risks to the infant before recommending Aclin during breastfeeding. Always consult your doctor or midwife for specific guidance based on your situation.

How to Store and Dispose of Aclin?

Storage Classification	Requirement
Temperature	Store at 20 C to 25 C (68 F to 77 F). Excursions permitted to 15 C to 30 C (59 F to 86 F).
Protection/Handling	Keep bottle tightly closed to protect from moisture. Store in the original container. Do not freeze.
Child Safety	Keep this and all medicines out of the sight and reach of children to prevent accidental exposure.

Official regulatory documents define the strict conditions necessary to maintain drug quality until the expiration date. Unused or expired Aclin must be disposed of safely. The preferred method is using a drug take-back program. If a take-back option is not readily available, the medicine should be mixed with an undesirable substance, such as used coffee grounds or dirt, placed into a sealed container or bag, and discarded in the household trash. Do not flush the medicine down a toilet or pour it down a sink unless the product's specific labeling instructs you to do so.